Immunotherapy for High-Grade Gliomas
NIH clinical trial Type Phase Eligibility criteria Primary outcome Dosing regimen Treatment groups NCT02311920 Checkpt 1 Newly diagnosed GBM Maximum safe dose In addition to TMZ, Arm I receives anti-CTLA4…
NEUROLOGY
Glioblastoma
Fig. 18.1 Survival rates of glioblastoma patients by age groups [1] Endogenous Risk Factors The cell of origin of glioblastoma is thought to be a neural stem cell (Box 18.1), but risk…
Targeted Therapy of IDH1-Mutated Tumors
Fig. 10.1 Molecular mechanisms of IDH-associated tumorigenesis. Wild-type IDH1/2 (wtIDH1/2) converts isocitrate (generated through the citric acid (TCA) cycle) into α-KG, producing NADPH in the process. Mutant IDH1/2 (mutIDH1/2) converts isocitrate…
Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted)
© Springer International Publishing AG 2017Jennifer Moliterno Gunel, Joseph M Piepmeier and Joachim M. Baehring (eds.)Malignant Brain Tumors 10.1007/978-3-319-49864-5_17 17. Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted) Charles Marc Leyrer1 , Erin Murphy1 and Manmeet Ahluwalia2 (1) 9500 Euclid Ave./T-28, Cleveland,…
Infiltrative Glioma
Fig. 16.1 Schematic overview of a possible clinical decision algorithm outside clinical trials for infiltrative glioma. IDH isocitrate dehydrogenase; ATRX alpha thalassemia mental retardation X-linked; MGMT O6 methylguanine methyltransferase; G–CIMP glioma-CpG…
Glioma Radiosensitizers: Exciting New Developments and Directions
© Springer International Publishing AG 2017Jennifer Moliterno Gunel, Joseph M Piepmeier and Joachim M. Baehring (eds.)Malignant Brain Tumors 10.1007/978-3-319-49864-5_15 15. Glioma Radiosensitizers: Exciting New Developments and Directions Christopher D. Corso1 and Ranjit S. Bindra1 (1) Department of Therapeutic Radiology, Yale…
Mapping the Brain for Primary Brain Tumor Surgery
Fig. 5.1 Illustrative case of a 50 years-old frustrated left-handed patient diagnosed with a left frontal glioblastoma revealed by headaches and language disturbances. a Preoperative T1-gadolinium enhanced MRI, showing a large enhancing…
Novel Delivery Strategies
Carrier Treatment Phase Study population # of patients Results Reference Nanoparticles Aminosilane-coated iron oxide particles and alternating magnetic fields I Recurrent grade IV astrocytoma 14 • Minor or no side…
Antiangiogenic Therapy for Malignant Gliomas
Trial Phase Disease type Patients (n) Arms Median PFS (mo) PFS-6 (%) Median OS (mo) Reference BRAIN 2 rGBM 167 BEV 4.2 42.6 9.2 [37] BEV + irinotecan 5.6 50.3 8.7 NCI 2 rGBM 48 BEV…
Targeting Aberrant Signaling Pathways
Fig. 9.1 Critical signaling pathways altered in malignant gliomas. Primary sequence alterations and significant copy number changes for the components of the a | RTK/RAS/PI3K, b | p53, and c |…
